CJC-1295 and Ipamorelin Dosage: The Blend, Protocol and Calculator

CJC-1295 (no-DAC) and ipamorelin are the two research peptides most often sold and dosed as a pair, usually from one blended vial. Neither has an approved dose, because neither has an approved product. No published human trial has tested the two given together.

This page covers what dosing sources describe for the blend, the reconstitution arithmetic, why the pairing is used, and what remains untested. For each compound on its own, see the CJC-1295 guide and the ipamorelin guide.

CJC-1295 and ipamorelin dosage: the common protocol

Clinic and vendor dosing guides most often describe 100-300 mcg of each peptide per injection, given together, subcutaneously. The schedule is once daily, five days a week with two days off, for an 8-12 week cycle with a break after. That is common practice, not a dose any trial has tested as this combination.

Common protocol

What is commonly used, not a dose established in trials. No regulator has set a dose for CJC-1295.

Dose per administration

100-300 mcg

How often

once daily, 5 days a week (5 days on, 2 off), usually the no-DAC form

Route

Subcutaneous injection

Cycle length

8-16 weeks

Break between cycles

4-6 weeks

Common vial size

5 mg

Timing

Before bed, on an empty stomach (at least two hours after the last meal).

Commonly paired with

Ipamorelin, 5-Amino-1MQ, AOD-9604, BPC-157

Sources describe the no-DAC form (mod GRF 1-29) dosed daily; the longer-acting with-DAC form is dosed roughly weekly at higher per-injection amounts, but that variant was not what the sourced daily protocols describe.

Plan a cycle in the protocol builder or work out injection volume in the dosage calculator.

The common CJC-1295 dose is 100-300 mcg, once daily, 5 days a week (5 days on, 2 off), usually the no-DAC form. From a 5 mg vial mixed with 2 mL of bacteriostatic water, 200 mcg is 8 units (0.08 mL) on a U-100 insulin syringe.

CJC-1295 5 mg vial: units per dose

Full 5 mg vial page: mixing, doses per vial, how long it lasts →

Water added	Concentration	1 unit =	100 mcg	200 mcg	300 mcg
1 mL	5 mg/mL	50 mcg	2 units	4 units	6 units
2 mL	2.5 mg/mL	25 mcg	4 units	8 units	12 units
3 mL	1.67 mg/mL	16.67 mcg	6 units	12 units	18 units

CJC-1295 10 mg vial: units per dose

Full 10 mg vial page: mixing, doses per vial, how long it lasts →

Water added	Concentration	1 unit =	100 mcg	200 mcg	300 mcg
1 mL	10 mg/mL	100 mcg	1 unit	2 units	3 units
2 mL	5 mg/mL	50 mcg	2 units	4 units	6 units
3 mL	3.33 mg/mL	33.33 mcg	3 units	6 units	9 units

All CJC-1295 vial sizes: 5 mg · 10 mg

Units are on a standard U-100 insulin syringe (100 units = 1 mL), rounded to the nearest half unit - half-unit marks are on 0.3 mL syringes. Water volumes are examples: more water means more units per dose, not more doses per vial. For any other vial or dose, use the dosage calculator.

How many 5 mg vials a cycle takes

Scenario	Dose	Doses a week	Weeks	Total	5 mg vials
Low end of the common protocol	100 mcg	5	8	4 mg	1
High end of the common protocol	300 mcg	5	16	24 mg	5

Whole vials, rounded up. Plan a cycle with your own numbers in the protocol builder. Keep mixed vials cold and use them within the window in how long reconstituted peptides last; where to inject: subcutaneous injection sites.

Common protocol

What is commonly used, not a dose established in trials. No regulator has set a dose for Ipamorelin. Sources differ, so the ranges below span them.

Dose per administration

100-300 mcg

How often

once nightly on 5 days a week in physician-supervised protocols, up to three times daily on an empty stomach in less structured use

Route

Subcutaneous injection

Cycle length

8-12 weeks

Break between cycles

4 weeks

Common vial size

5 mg

Timing

On an empty stomach - commonly before bed, 20-30 minutes before eating, or right after a workout.

Commonly paired with

CJC-1295

A named clinic network (Beverly Hills Rejuvenation Center) describes pairing ipamorelin with CJC-1295 (no-DAC) in one bedtime injection, 5 nights a week, starting at 100 mcg and titrating to 200-300 mcg; a vendor guide describes the same dose range used up to three times daily rather than once. Both agree on dose (100-300 mcg), 8-12 week cycles and a roughly 4-week break; they differ materially on how often per week, so that range is kept wide and flagged as varying.

Plan a cycle in the protocol builder or work out injection volume in the dosage calculator.

The common Ipamorelin dose is 100-300 mcg, once nightly on 5 days a week in physician-supervised protocols, up to three times daily on an empty stomach in less structured use. From a 5 mg vial mixed with 2 mL of bacteriostatic water, 200 mcg is 8 units (0.08 mL) on a U-100 insulin syringe.

Ipamorelin 5 mg vial: units per dose

Full 5 mg vial page: mixing, doses per vial, how long it lasts →

Water added	Concentration	1 unit =	100 mcg	200 mcg	300 mcg
1 mL	5 mg/mL	50 mcg	2 units	4 units	6 units
2 mL	2.5 mg/mL	25 mcg	4 units	8 units	12 units
3 mL	1.67 mg/mL	16.67 mcg	6 units	12 units	18 units

Ipamorelin 10 mg vial: units per dose

Full 10 mg vial page: mixing, doses per vial, how long it lasts →

Water added	Concentration	1 unit =	100 mcg	200 mcg	300 mcg
1 mL	10 mg/mL	100 mcg	1 unit	2 units	3 units
2 mL	5 mg/mL	50 mcg	2 units	4 units	6 units
3 mL	3.33 mg/mL	33.33 mcg	3 units	6 units	9 units

All Ipamorelin vial sizes: 5 mg · 10 mg

Units are on a standard U-100 insulin syringe (100 units = 1 mL), rounded to the nearest half unit - half-unit marks are on 0.3 mL syringes. Water volumes are examples: more water means more units per dose, not more doses per vial. For any other vial or dose, use the dosage calculator.

How many 5 mg vials a cycle takes

Scenario	Dose	Doses a week	Weeks	Total	5 mg vials
Low end of the common protocol	100 mcg	5	8	4 mg	1
High end of the common protocol	300 mcg	21	12	75.6 mg	16

Whole vials, rounded up. Plan a cycle with your own numbers in the protocol builder. Keep mixed vials cold and use them within the window in how long reconstituted peptides last; where to inject: subcutaneous injection sites.

Two dosing sources show the range:

• Beverly Hills Rejuvenation Center: starts at 100 mcg of each peptide per dose and titrates up to 200-300 mcg of each, once daily at bedtime on an empty stomach. This is the same source already recorded for ipamorelin’s own protocol above. It says this combination has not been tested in a published human randomized controlled trial.
• PerfectB: a blended vial on a slower titration. It starts near 0.3 mg combined in week one and reaches about 1 mg combined by month two. Dosing is five days on and two off, in monthly cycles of up to three runs before a longer break. It says its numbers come from clinical experience, not a controlled trial with a comparison group.

See both sources directly: Beverly Hills Rejuvenation Center’s guide and PerfectB’s guide.

The two sources agree on the broad shape: daily subcutaneous dosing, empty-stomach or bedtime timing, and cycles measured in months with a break after. They disagree on the exact titration curve, which is why the common-protocol figures above are a range rather than one number.

Why CJC-1295 and ipamorelin are paired

The two compounds act on different receptors that end in the same pituitary response. CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) and acts on the pituitary’s GHRH receptor. Ipamorelin acts on the ghrelin receptor (GHS-R1a), the pathway Raun 1998 - Raun K, Hansen BS, Johansen NL et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61., in the references below identified it working through in animal and in vitro research.

Sources describing the blend say pairing a GHRH-receptor analogue with a ghrelin-receptor agonist produces a larger growth hormone pulse than either alone. They say the two receptors act on the pulse through different, complementary steps. That is a mechanism argument repeated widely in clinic and vendor material. It is not evidence that the combination has been tested in people. The separate evidence for each compound is in the CJC-1295 guide and the ipamorelin guide.

The blended vial, and the reconstitution arithmetic

The product most often sold for this pairing is a single vial holding both peptides, rather than two vials drawn separately. Two independent sources describe the same composition: Palmetto Peptides’ guide and Core Peptides’ product listing. Both describe a 10 mg total vial of 5 mg CJC-1295 (no-DAC) and 5 mg ipamorelin, a 1:1 ratio. Palmetto’s dosing tables use 100 mcg of each peptide per administration as their reference dose, the low end of the common protocol above.

Reconstitution volume changes the concentration, not the total content. Palmetto Peptides’ guide lays out several options for a 5 mg/5 mg (10 mg total) vial:

• 1 mL of bacteriostatic water gives 5 mg/mL of each peptide.
• 2 mL gives 2.5 mg/mL of each.
• 3 mL gives about 1.67 mg/mL of each.

Here is one worked example, not a recommendation for any vial. Reconstituting a 10 mg (5 mg/5 mg) vial with 2 mL of bacteriostatic water gives 2.5 mg (2,500 mcg) of each peptide per mL. The table below gives the syringe units for doses of each peptide from that vial. The arithmetic only holds for that exact vial and dilution; a different vial size or amount of diluent changes every number. Use the dosage calculator for your own vial rather than reusing this example.

What no published trial has tested

Each compound has its own published human trial data, and neither trial used anything like the blend protocol above.

• A randomised trial in healthy adults Teichman 2006 - Teichman SL, Neale A, Lawrence B et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805., in the references below tested CJC-1295 with-DAC alone, as single or repeated subcutaneous doses of 30 or 60 mcg/kg. That is a different form, dose unit and schedule than the daily no-DAC blend described here.
• Ipamorelin’s two published human studies gave it alone, by intravenous infusion rather than subcutaneous injection. One was a pharmacokinetic study Gobburu 1999 - Gobburu JV, Agersø H, Jusko WJ et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-6., in the references below. The other was a Phase 2 postoperative trial Beck 2014 - Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34., in the references below that found no significant benefit over placebo.

Full detail is on their own dosing pages: CJC-1295 dosage and ipamorelin dosage.

No published human study has given CJC-1295 and ipamorelin together, in any dose, route or schedule. The blend protocol above comes entirely from clinic and vendor sources describing current practice, and those sources say so themselves.

Side effects and risks

At the doses each trial tested, on its own, neither published study reported a serious adverse reaction directly attributed to the compound. The CJC-1295 with-DAC trial Teichman 2006 - Teichman SL, Neale A, Lawrence B et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805., in the references below reported no serious adverse reactions. The ipamorelin Phase 2 trial Beck 2014 - Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34., in the references below reported treatment-emergent adverse events in a majority of both its treatment and placebo groups, without singling out a severe reaction specific to ipamorelin.

None of that is safety data for the blend. Neither compound has long-term human safety data, and no trial has tested them together at the blend’s doses and schedule. That carries risks, including unknown interaction effects, that this page cannot quantify because no source has measured them. A vial bought outside the trial system carries no verified content, purity or actual concentration for either peptide.

Is CJC-1295 and ipamorelin legal?

Neither compound has FDA approval, in any form. Both are sold as research chemicals rather than legally marketed human drugs. Both are named in the current WADA Prohibited List as growth hormone releasing factors and secretagogues, prohibited at all times in sport. Combining them in one vial does not change either compound’s regulatory status: it is still two unapproved substances, not a reviewed product.

Each compound’s own page has the jurisdiction-specific detail: CJC-1295 and ipamorelin. For how US law treats research-use-only peptides generally, see research peptides and the law. For regulatory changes as they happen, see the US peptide regulation tracker.

For where research-labelled peptides are sourced, see this site’s research-access page. It sends readers to a specific research-peptide supplier and discloses that relationship on that page. The vendors I check that sell the blend, with dated prices: where to buy CJC-1295 and ipamorelin.

Related

• CJC-1295: with DAC and without DAC, explained
• Ipamorelin: what the clinical record shows
• CJC-1295 dosage: the trial data
• Ipamorelin dosage: the study doses
• Plan a cycle in the protocol builder
• Where to buy CJC-1295 and ipamorelin: checked vendors and prices
• Dosage calculator
• US peptide regulation tracker

Common questions

What is the usual CJC-1295 and ipamorelin dosage?

Clinic and vendor dosing guides most often describe 100-300 mcg of each peptide per injection, given together, subcutaneously. The schedule is once daily, five days a week with two days off, for an 8-12 week cycle with a break after. That is common practice, not a dose any trial has tested as a combination.

What comes in a CJC-1295 and ipamorelin blend vial?

The product most often sold is a single vial holding 5 mg of CJC-1295 (no-DAC) and 5 mg of ipamorelin, for 10 mg total. One reconstitution and one injection delivers both peptides in equal amounts. Some sellers also offer separate single vials of each, drawn together by hand.

Why are CJC-1295 and ipamorelin used together?

They act on two different receptors that both end in a growth hormone pulse from the pituitary. CJC-1295 is a GHRH-receptor analogue, and ipamorelin acts on the ghrelin receptor (GHS-R1a). Sources say combining the two produces a larger pulse than either alone. That is a mechanism argument, not a trial finding for this blend.

Has the CJC-1295 and ipamorelin combination been tested in a clinical trial?

No. Each compound has its own published human trial data (see the individual dosing pages), but I could not find a published human trial that gave the two together. Clinic and vendor sources say so themselves: the protocol reflects supervised experience, not a controlled trial.

How do I work out reconstitution and injection volume for the blend?

That depends on your specific vial, its total mg content and how much diluent was added, which this page cannot know. Use the dosage calculator for your own vial; it does the calculation, it does not choose a dose.

What are the side effects of combining CJC-1295 and ipamorelin?

The published trials for each compound separately reported no serious adverse reactions at the doses they tested, in small, short, clinically monitored studies. No published trial has looked at side effects of the two given together at the common blend doses and schedule. The combination has no dedicated human safety data.

Does CJC Ipamorelin affect testosterone?

I found no human study measuring testosterone with the blend or with either peptide alone. The CJC-1295 trials measured growth hormone and IGF-1. In pigs, ipamorelin did not change LH or FSH, the pituitary hormones that drive testosterone production. That is an animal finding, not evidence about people. See the [ipamorelin guide](/compounds/ipamorelin/) for its separate evidence.

How long does it take to see results from CJC-1295 Ipamorelin therapy?

No study has measured results from the blend, so there is no evidence-based timeline. The human data are hormone measurements. Ipamorelin's growth hormone burst peaked about 40 minutes after an intravenous dose. CJC-1295 with DAC, a longer-acting form than the no-DAC peptide in the blend, raised IGF-1 for 9-11 days after one injection. The 8-12 week cycle is common practice, not a trial-tested figure.

Does ipamorelin target belly fat?

I found no human study showing that ipamorelin reduces belly fat or any other fat. In mice, twice-daily ipamorelin increased fat pad weight and, in mice with normal growth hormone, food intake. That is the opposite of the marketing claim, though only an animal finding. A Phase 2 trial of CJC-1295 in people with HIV-associated visceral (abdominal) obesity was terminated in 2006 without posting results.

References (10 sources)

Show

Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.

1. 1.Teichman SL, Neale A, Lawrence B et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.Randomised trialPMID 16352683
2. 2.Gobburu JV, Agersø H, Jusko WJ et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-6.Randomised trialPMID 10496658
3. 3.Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34.Randomised trialPMID 25331030
4. 4.Raun K, Hansen BS, Johansen NL et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61.StudyPMID 9849822
5. 5.Lall S, Tung LY, Ohlsson C et al. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001;280(1):132-8.StudyPMID 11162489
6. 6.America's Poison Centers - confirms 1-800-222-1222 as the national Poison Control number, free and confidential, 24 hours a day.- America's Poison Centersother
7. 7.Beverly Hills Rejuvenation Center’s guide- bhrcenter.comother
8. 8.PerfectB’s guide- perfectb.comother
9. 9.Palmetto Peptides’ guide- palmettopeptides.comother
10. 10.Core Peptides’ product listing- corepeptides.comother

Keep reading

Related guides

All guides →

• aod-9604 cjc-1295 ipamorelin dosageAOD-9604 + CJC-1295 + Ipamorelin Dosage: The Blend, Protocol and CalculatorAOD-9604, CJC-1295 and ipamorelin dosage: the common 12 mg triple-blend vial two real sources describe, reconstitution math, and why the three are combined.5 min readRead guide→
• bpc 157 dosageBPC-157 Dosage Chart and Calculator: Protocol and Study DosesBPC-157 dosage chart: units per dose by vial size for the 250-500 mcg common protocol, a calculator, and the doses five small human studies used.5 min readRead guide→
• cjc-1295 ghrp-2 dosageCJC-1295 + GHRP-2 Dosage: The Blend, Protocol and CalculatorCJC-1295 and GHRP-2 dosage: the common 10 mg blend vial two real sources describe, reconstitution math, why the pair is used, and side effects.5 min readRead guide→
• cjc-1295 dosageCJC-1295 Dosage Chart and Calculator: Protocol and Trial DataCJC-1295 dosage chart: units per dose by vial size for the 100-300 mcg no-DAC common protocol, a calculator, and the only human trial data (with-DAC form).4 min readRead guide→
• ipamorelin dosageIpamorelin Dosage Chart and Calculator: Protocol, Study DosesIpamorelin dosage chart: units per dose by vial size for the 100-300 mcg common protocol, a calculator, and the IV doses two published human studies used.4 min readRead guide→
• melanotan 2 dosageMelanotan 2 Dosage: Common Protocol, Study Dose and CalculatorMelanotan 2 dosage: the daily loading-dose common protocol, the 0.01-0.03 mg/kg doses small published trials used, and an injection calculator.5 min readRead guide→